NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.
Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.
To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand ‘memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity.
Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care.
Two microscopic views of CAR-NK cell rapid response to tumor antigen, illustrating CAR-NK cell therapy’s potential in solid tumor treatment.
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways…
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma…
Basic Natural Killer (NK) Cell Immunobiology
NAKI’s CD147-CAR-NK technology is:
CAR-NK cells are a promising cell therapy. The reasons can be proposed as follows: